Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

763
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
763

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct patterns of default mode network functional connectivity between adolescents with bipolar disorder and major depressive disorder.

Frontiers in psychiatry·2026
Same author

Transdiagnostic mapping of common and specific regional homogeneity alterations across affective and psychotic disorders.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Transdiagnostic mapping of brain structural abnormalities and network-constrained gray matter atrophy patterns across affective and psychotic disorders.

Molecular psychiatry·2026
Same author

Antitumor efficacy and safety of locoregional [<sup>177</sup>Lu]Lu-RM26 radionuclide therapy in glioblastoma.

European journal of nuclear medicine and molecular imaging·2026
Same author

Development and application of a dual RT-qPCR assay for the differential detection of bovine rhinitis virus genotypes A and B.

Journal of virological methods·2026
Same author

Evaluation of optimal ClearInfinity artificial intelligence deep learning reconstruction algorithm weights with a 70-kVp tube voltage combined with "dual-low" abdominal computed tomography angiography.

Quantitative imaging in medicine and surgery·2026

Related Experiment Video

Updated: Apr 7, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.3K

Dual-targeted 68 Ga-NOTA-3P-TATE-RGD PET/CT in Radioactive-iodine Negative Differentiated Thyroid Cancer : An

Jialin Xiang1, Yanwei Wang1, Xin Zhang1

  • 1Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China.

Clinical Nuclear Medicine
|April 6, 2026
PubMed
Summary

This study shows that 68Ga-NOTA-3P-TATE-RGD PET/CT is a feasible imaging tool for differentiated thyroid cancer (DTC) that does not respond to radioactive iodine. It offers complementary diagnostic value to 18F-FDG PET/CT, particularly for detecting bone and brain metastases.

Keywords:
PET/CTSSTR2TATE-RGDdifferentiated thyroid cancerintegrin αvβ3metastases

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

Related Experiment Videos

Last Updated: Apr 7, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.3K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceuticals

Background:

  • Differentiated thyroid cancer (DTC) can become resistant to radioactive iodine treatment.
  • New imaging agents are needed to detect recurrent or metastatic DTC when radioactive iodine scans are negative.
  • This study evaluates a novel dual-targeted radiopharmaceutical, 68Ga-NOTA-3P-TATE-RGD, for imaging these challenging cases.

Purpose of the Study:

  • To assess the clinical feasibility of 68Ga-NOTA-3P-TATE-RGD PET/CT in patients with radioactive-iodine-negative DTC.
  • To compare the diagnostic performance of 68Ga-NOTA-3P-TATE-RGD PET/CT with standard 18F-FDG PET/CT.
  • To explore the potential of this new agent in identifying specific genetic subtypes of DTC.

Main Methods:

  • Twenty-two patients with radioactive-iodine-negative DTC underwent both 68Ga-NOTA-3P-TATE-RGD PET/CT and 18F-FDG PET/CT within a week.
  • Diagnostic accuracy and semiquantitative parameters were compared between the two imaging modalities.
  • Preliminary analysis correlated PET uptake with known gene mutation data.

Main Results:

  • 68Ga-NOTA-3P-TATE-RGD detected 45 exclusive lesions, notably in bone and brain.
  • 18F-FDG PET/CT identified 75 exclusive lesions, primarily in lymph nodes and lungs.
  • The dual-targeted agent showed superior specificity (92.3% vs 70.6%) and a higher tumor-background ratio for bone metastases.
  • 68Ga-NOTA-3P-TATE-RGD uptake was highest in TERT promoter-mutant lesions, while 18F-FDG uptake was maximal in BRAF-mutant lesions.

Conclusions:

  • 68Ga-NOTA-3P-TATE-RGD PET/CT is clinically feasible for radioactive-iodine-negative DTC.
  • This agent provides complementary information to 18F-FDG PET/CT, enhancing the detection of bone and brain metastases.
  • High uptake in TERT-associated aggressive subtypes suggests potential for specific disease characterization and targeted therapy selection.